$54.81 +2.34 (%) Incyte Corp - NASDAQ

Oct. 23, 2014 | 03:55 PM

Partner Headlines

  1. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga | Oct. 20, 2014 | 16:58PM EST
  2. UPDATE: Incyte Partners With Genetech to Help With Trials

    Benzinga | Jul. 30, 2014 | 08:43AM EST
  3. Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc.

    GuruFocus | Jun. 9, 2014 | 12:16PM EST
  4. Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN

    GuruFocus | Jun. 8, 2014 | 18:27PM EST
  5. Surges In Biotech Short Interest (INCY, PCYC, RGEN)

    Benzinga | May. 11, 2014 | 16:35PM EST
  6. Mid-Day Losers Mar. 7, 2014: PXLW, ALOG, ALSK, NMRX, NLNK, EMAN

    Benzinga | Mar. 7, 2014 | 11:34AM EST
  7. Morning Movers for Mar. 7, 2014: SKUL, DLIA, BIG, GTAT, CCRN, FL Moving Higher; NLNK, FEYE, SWY, FCEL Lower

    Benzinga | Mar. 7, 2014 | 09:04AM EST
  8. US Stock Futures Edge Higher; All Eyes On Jobs Report

    Benzinga | Mar. 7, 2014 | 07:37AM EST
  9. UPDATE: Bank of America Reinstates Coverage on Incyte on Two Oncology Platforms

    Benzinga | Feb. 26, 2014 | 08:19AM EST
  10. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga | Feb. 13, 2014 | 10:18AM EST
  11. Incyte Q4 swings to a loss

    IBD | Feb. 12, 2014 | 18:43PM EST
  12. Merck soars on cancer deal

    IBD | Feb. 5, 2014 | 18:56PM EST
  13. Merck Q4 Misses, But Cancer Deals Ignite Stock

    IBD | Feb. 5, 2014 | 11:48AM EST
  14. Incyte Names Hervé Hoppenot President and CEO

    Benzinga | Jan. 13, 2014 | 05:49AM EST
  15. Incyte Reports Jakafi Data Continues to Show Improved Overall Survival for Patients with Myelofibrosis at ASH

    Benzinga | Dec. 9, 2013 | 12:48PM EST
  16. UPDATE: Piper Jaffray Initiates Coverage on Incyte as 2014 Biotech Sector Outlook Remains Strong

    Benzinga | Nov. 27, 2013 | 11:16AM EST
  17. Incyte Completes Offering of $750M of Convertible Senior Notes

    Benzinga | Nov. 14, 2013 | 16:15PM EST
  18. Geron Revealed Positive Imetelstat Results Amidst Data Concerns

    Benzinga | Nov. 7, 2013 | 13:10PM EST
  19. Incyte Announces Positive Phase II Clinical Trial Results of Oral JAK1 Inhibitor in Patients with Active RA

    Benzinga | Oct. 28, 2013 | 22:43PM EST
  20. Incyte Reports Positive Results from Phase II Clinical Trial of Oral JAK1 Inhibitor

    Benzinga | Oct. 3, 2013 | 06:03AM EST
  21. Weekly CEO Sells Highlight: ExOne Co, Atmel Corporation, Best Buy and Incyte Corp Ltd.

    GuruFocus | Sep. 22, 2013 | 15:31PM EST
  22. Weekly CFO Sells Highlight: INTU, INCY, RLD, MIDD, XONE

    GuruFocus | Sep. 16, 2013 | 02:05AM EST
  23. UPDATE: Jefferies Raises PT on Incyte Following Favorable Phase 2 RECAP Data

    Benzinga | Aug. 22, 2013 | 11:44AM EST
  24. Incyte surges on drug report

    IBD | Aug. 21, 2013 | 18:43PM EST
  25. Benzinga Market Wrap For August 21: FOMC Minutes Send Markets Spinning

    Benzinga | Aug. 21, 2013 | 16:24PM EST
  26. Mid-Afternoon Market Update: Retailers Hurting As Lowe's Rises

    Benzinga | Aug. 21, 2013 | 15:47PM EST
  27. Mid-Day Market Update: Staples Shares Slip On Weak Earnings

    Benzinga | Aug. 21, 2013 | 12:52PM EST
  28. UPDATE: Canaccord Raises PT on Incyte Following Phase 2 RECAP Data Release

    Benzinga | Aug. 21, 2013 | 11:42AM EST
  29. Incyte Stock Soars As Drug Fights Pancreatic Cancer

    IBD | Aug. 21, 2013 | 11:36AM EST
  30. UPDATE: Bank of America Raises PT on Incyte on Compelling New Data

    Benzinga | Aug. 21, 2013 | 11:31AM EST
  31. Mid-Morning Market Update: Markets Mostly Lower; Lowe's Posts Upbeat Profit

    Benzinga | Aug. 21, 2013 | 10:30AM EST
  32. Stocks Hitting 52-Week Highs

    Benzinga | Aug. 21, 2013 | 10:12AM EST
  33. Benzinga's Top Pre-Market Gainers

    Benzinga | Aug. 21, 2013 | 08:09AM EST
  34. UPDATE: UBS Investment Research Raises PT on Incyte Following 2Q13 Results

    Benzinga | Aug. 2, 2013 | 11:09AM EST
  35. Mid-Afternoon Market Update: Bernanke Press Conference Leads to Drop in the Markets

    Benzinga | Dec. 12, 2012 | 08:56AM EST
  36. Mid-Day Market Update: Fed to Continue Stimulus, Markets Rise

    Benzinga | Dec. 12, 2012 | 07:26AM EST
  37. Gilead Acquiring YM Biosciences For Cancer Drug

    IBD | Dec. 12, 2012 | 03:22AM EST
  38. Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis

    Benzinga | Nov. 15, 2012 | 01:03AM EST
  39. Incyte Corp. Reports Operating Results (10-Q)

    GuruFocus | Nov. 1, 2012 | 13:34PM EST
  40. UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Lowers PT on Incyte Corporation

    Benzinga | Sep. 5, 2012 | 04:26AM EST
  41. Benzinga's Top Initiations

    Benzinga | Aug. 7, 2012 | 01:31AM EST
  42. Incyte Corp. Reports Operating Results (10-Q)

    GuruFocus | Aug. 3, 2012 | 13:26PM EST
  43. Biotechs In Motion As New Drug Pipeline Brims

    IBD | Jul. 27, 2012 | 10:27AM EST
  44. Merck &, Questcor Pharmaceuticals, Other Stocks Hit 52-Week Highs Monday

    FoxBusiness | Jul. 9, 2012 | 06:33AM EST
  45. Lennar Corporation, D.R. Horton Among Stocks Hitting 52-Week Highs Thursday

    FoxBusiness | Jul. 5, 2012 | 10:33AM EST
  46. Social Media Outlook for Tuesday July 3 (INCY, MCS, CLNE, OPEN)

    Benzinga | Jul. 3, 2012 | 07:10AM EST
  47. Health Care Sector Wrap

    FoxBusiness | Jul. 2, 2012 | 10:51AM EST
  48. Piper Jaffray Recommends Incyte (INCY)

    Benzinga | Jun. 8, 2012 | 08:59AM EST
  49. Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis

    Benzinga | Jun. 8, 2012 | 04:47AM EST
  50. The Definitive Biotech ETF Guide (IBB, XBI, FBT)

    Benzinga | May. 21, 2012 | 07:35AM EST
Trading Center